Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

SIMPLE SUMMARY: The prognosis for gastric cancer remains poor, with a median overall survival of approximately 1 year. Ramucirumab and pembrolizumab have each demonstrated antitumor activity and a favorable safety profile as treatments for patients with advanced gastric/gastroesophageal junction (G/...

Descripción completa

Detalles Bibliográficos
Autores principales: Chau, Ian, Penel, Nicolas, Soriano, Andres O., Arkenau, Hendrik-Tobias, Cultrera, Jennifer, Santana-Davila, Rafael, Calvo, Emiliano, Le Tourneau, Christophe, Zender, Lars, Bendell, Johanna C., Mi, Gu, Gao, Ling, McNeely, Samuel Clark, Oliveira, Joana M., Ferry, David, Herbst, Roy S., Fuchs, Charles S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602637/
https://www.ncbi.nlm.nih.gov/pubmed/33076423
http://dx.doi.org/10.3390/cancers12102985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602637/
https://www.ncbi.nlm.nih.gov/pubmed/33076423
http://dx.doi.org/10.3390/cancers12102985

Ejemplares similares